As of September 30, 2026, Starling Oncology, Inc. carries a market capitalization of 644.58M, placing it among publicly traded companies globally. Its enterprise value stands at 710.42M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 644.58M |
| Enterprise Value | 710.42M |
Starling Oncology, Inc.'s next confirmed earnings release is scheduled for March 11, 2027.
| Earnings Date | 3/11/2027 |
As of September 30, 2026, Starling Oncology, Inc. has 101.99M shares outstanding.
| Shares Outstanding | 101.99M |
These figures are as of September 30, 2026. The price-to-sales ratio is 1.05, and the price-to-book ratio stands at -17.26.
| PS Ratio | 1.05 |
| PB Ratio | -17.26 |
| P/TBV Ratio | -12.06 |
| P/FCF Ratio | 34.49 |
| P/OCF Ratio | 28.11 |
These figures are as of September 30, 2026. The EV/Sales ratio of 1.15 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 710.42M versus a market cap of 644.58M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 1.15 |
As of September 30, 2026, Starling Oncology, Inc. maintains a current ratio of 1.11, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -275.01, indicating conservative leverage, while an interest coverage ratio of -1.92 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.11 |
| Quick Ratio | 0.79 |
| Debt / Equity | -275.01 |
| Debt / EBITDA | -7.13 |
| Interest Coverage | -1.92 |
These figures cover the twelve months ended September 30, 2026. Return on assets (ROA) is negative at -20.23, reflecting losses generated across the asset base. The company generates approximately 967,936.04 in revenue per employee across its workforce of 641.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 18.61 indicates how many times Starling Oncology, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Assets (ROA) | -20.23 |
| Revenue Per Employee | 967,936.04 |
| Employee Count | 641.00 |
| Inventory Turnover | 18.61 |
These figures are as of the close on November 16, 2026.
| 50-Day Moving Average | 6.18 |
Over the twelve months ended September 30, 2026, Starling Oncology, Inc. generated 620.45M in revenue and converted that into -35.54M in net income, yielding earnings per share of -0.35. EBITDA reached -14.41M, while operating income came in at -21.02M.
| Revenue | 620.45M |
| Gross Profit | 103.92M |
| Operating Income | -21.02M |
| Pretax Income | -35.54M |
| Net Income | -35.54M |
| EBITDA | -14.41M |
| EBIT | -21.02M |
| Earnings Per Share (EPS) | -0.35 |
As of September 30, 2026, Starling Oncology, Inc. holds 36.90M in cash and equivalents against 102.73M in total debt, resulting in a net debt position of 40.63M. Total book value stands at -37.35M, with working capital of 13.99M providing operational flexibility.
| Cash & Cash Equivalents | 36.90M |
| Total Debt | 102.73M |
| Net Debt | 40.63M |
| Equity (Book Value) | -37.35M |
| Book Value Per Share | -0.37 |
| Working Capital | 13.99M |
Starling Oncology, Inc. produced 23.10M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -4.27M in capital expenditures, free cash flow totaled 18.83M - equivalent to 0.18 per share.
| Operating Cash Flow | 23.10M |
| Capital Expenditures | -4.27M |
| Free Cash Flow | 18.83M |
| FCF Per Share | 0.18 |
Over the twelve months ended September 30, 2026, Starling Oncology, Inc. posted a gross margin of 16.75, reflecting its pricing power and cost economics. The operating margin of -3.39 and net profit margin of -5.73 provide insight into operational efficiency.
| Gross Margin | 16.75 |
| Operating Margin | -3.39 |
| Pretax Margin | -5.73 |
| Profit Margin | -5.73 |
| EBITDA Margin | -2.32 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield stands at 2.90, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.49, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Starling Oncology, Inc. shareholders.
| Shareholder Yield | 1.49 |
| FCF Yield | 2.90 |
As of September 30, 2026, Starling Oncology, Inc. has an Altman Z-Score of 2.58, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.58 |